Icahn School of Medicine at Mount Sinai-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN

    Schizophrenia, Vol. 10, Núm. 1

2023

  1. Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: The OPTiMiSE study

    Psychological Medicine, Vol. 53, Núm. 8, pp. 3471-3479

2021

  1. Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study

    Schizophrenia bulletin, Vol. 47, Núm. 2, pp. 444-455

2018

  1. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

    The Lancet Psychiatry, Vol. 5, Núm. 10, pp. 797-807

2016

  1. Comorbilidad con el eje II y funcionalidad en pacientes graves con trastorno límite de la personalidad

    Actas Espanolas de Psiquiatria, Vol. 44, Núm. 6, pp. 212-221

2008

  1. Enhanced cortisol suppression in eating disorders with impulsive personality features

    Psychiatry Research, Vol. 158, Núm. 1, pp. 93-97

2000

  1. Decreased platelet monoamine oxidase activity in female anorexia nervosa

    Acta Psychiatrica Scandinavica, Vol. 101, Núm. 3, pp. 226-230

  2. Decreased platelet monoamine oxidase activity in female bulimia nervosa

    European Neuropsychopharmacology, Vol. 10, Núm. 2, pp. 113-117

1996

  1. Dismorfofobia y espectro obsesivo-compulsivo

    Actas Espanolas de Psiquiatria, Vol. 24, Núm. 6, pp. 331-337